132 related articles for article (PubMed ID: 19274614)
1. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03.
Hitz F; Martinelli G; Zucca E; von Moos R; Mingrone W; Simcock M; Peterson J; Cogliatti SB; Bertoni F; Zimmermann DR; Ghielmini M;
Hematol Oncol; 2009 Sep; 27(3):154-9. PubMed ID: 19274614
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Dumontet C; Morschhauser F; Solal-Celigny P; Bouafia F; Bourgeois E; Thieblemont C; Leleu X; Hequet O; Salles G; Coiffier B
Br J Haematol; 2001 Jun; 113(3):772-8. PubMed ID: 11380469
[TBL] [Abstract][Full Text] [Related]
3. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Garbo LE; Flynn PJ; MacRae MA; Rauch MA; Wang Y; Kolibaba KS
Invest New Drugs; 2009 Oct; 27(5):476-81. PubMed ID: 18953490
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Kouroukis CT; Fernandez LA; Crump M; Gascoyne RD; Chua NS; Buckstein R; Turner R; Assouline S; Klasa RJ; Walsh W; Powers J; Eisenhauer E
Leuk Lymphoma; 2011 Mar; 52(3):394-9. PubMed ID: 21323520
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
Oh SY; Kim WS; Lee DH; Kim SJ; Kim SH; Ryoo BY; Kang HJ; Choi YJ; Chung JS; Kim HJ; Suh C
Invest New Drugs; 2010 Apr; 28(2):171-7. PubMed ID: 19421710
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.
Morschhauser F; Depil S; Jourdan E; Wetterwald M; Bouabdallah R; Marit G; Solal-Céligny P; Sebban C; Coiffier B; Chouaki N; Bauters F; Dumontet C
Ann Oncol; 2007 Feb; 18(2):370-5. PubMed ID: 17074972
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
Fosså A; Santoro A; Hiddemann W; Truemper L; Niederle N; Buksmaui S; Bonadonna G; Seeber S; Nowrousian MR
J Clin Oncol; 1999 Dec; 17(12):3786-92. PubMed ID: 10577850
[TBL] [Abstract][Full Text] [Related]
8. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
9. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas.
Lin MH; Chen JS; Chen HH; Su WC
Chemotherapy; 2003 Jun; 49(3):154-8. PubMed ID: 12815209
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M; Avigdor A; Ribakovsky E; Nagler A; Kedmi M
Acta Haematol; 2019; 141(2):84-90. PubMed ID: 30630175
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Bass AJ; Gockerman JP; Hammett E; DeCastro CM; Adams DJ; Rosner GL; Payne N; Davis P; Foster T; Moore JO; Rizzieri DA
J Clin Oncol; 2002 Jul; 20(13):2995-3000. PubMed ID: 12089230
[TBL] [Abstract][Full Text] [Related]
15. [A phase II multicenter study of gemcitabine in non small cell lung cancers].
Le Chevalier T; Gottfried M; Gatzemeier U; Shepherd F; Weynants P; Cottier B; Groen HJ; Rosso R; Mattson K; Cortes-Funes H; Tonato M; Burkes RL; Voi M; Ponzio A
Bull Cancer; 1997 Mar; 84(3):282-8. PubMed ID: 9207875
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Offidani M; Mele A; Corvatta L; Marconi M; Malerba L; Olivieri A; Rupoli S; Alesiani F; Leoni P
Leuk Lymphoma; 2002 Jun; 43(6):1273-9. PubMed ID: 12152996
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
19. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
Gatzemeier U; Shepherd FA; Le Chevalier T; Weynants P; Cottier B; Groen HJ; Rosso R; Mattson K; Cortes-Funes H; Tonato M; Burkes RL; Gottfried M; Voi M
Eur J Cancer; 1996 Feb; 32A(2):243-8. PubMed ID: 8664035
[TBL] [Abstract][Full Text] [Related]
20. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
